- Home
- EVGN vs EQ Comparison
EVGN vs EQ Comparison
Compare EVGN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGN
- EQ
- Stock Information
- Founded
- EVGN 1999
- EQ 2017
- Country
- EVGN Israel
- EQ United States
- Employees
- EVGN N/A
- EQ N/A
- Industry
- EVGN Agricultural Chemicals
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- EVGN Industrials
- EQ Health Care
- Exchange
- EVGN Nasdaq
- EQ Nasdaq
- Market Cap
- EVGN 11.3M
- EQ 12.2M
- IPO Year
- EVGN N/A
- EQ 2018
- Fundamental
- Price
- EVGN $1.33
- EQ $0.32
- Analyst Decision
- EVGN Strong Buy
- EQ Buy
- Analyst Count
- EVGN 1
- EQ 3
- Target Price
- EVGN $3.50
- EQ $3.00
- AVG Volume (30 Days)
- EVGN 5.5M
- EQ 1.8M
- Earning Date
- EVGN 08-21-2025
- EQ 08-07-2025
- Dividend Yield
- EVGN N/A
- EQ N/A
- EPS Growth
- EVGN N/A
- EQ N/A
- EPS
- EVGN N/A
- EQ N/A
- Revenue
- EVGN $6,765,000.00
- EQ $30,406,000.00
- Revenue This Year
- EVGN N/A
- EQ N/A
- Revenue Next Year
- EVGN $113.18
- EQ N/A
- P/E Ratio
- EVGN N/A
- EQ N/A
- Revenue Growth
- EVGN N/A
- EQ N/A
- 52 Week Low
- EVGN $0.95
- EQ $0.27
- 52 Week High
- EVGN $6.80
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- EVGN 49.73
- EQ 43.51
- Support Level
- EVGN $1.26
- EQ $0.27
- Resistance Level
- EVGN $1.44
- EQ $0.36
- Average True Range (ATR)
- EVGN 0.11
- EQ 0.04
- MACD
- EVGN -0.02
- EQ 0.00
- Stochastic Oscillator
- EVGN 21.62
- EQ 56.67
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.